Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Acalabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 24,003Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma
    FDA Approves Acalabrutinib for Mantle Cell Lymphoma

    17 Jan 2025

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html

    PRESS RELEASE
    17 Jan 2025
    Share Share
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma
    CALQUENCE® Gets US Priority Review For Mantle Cell Lymphoma

    03 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241003958806/en

    BUSINESSWIRE
    03 Oct 2024
    Share Share
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
    AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia

    30 Jul 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html

    PRESS RELEASE
    30 Jul 2024
    Share Share
    CALQUENCE Plus Chemoimmunotherapy Reduced MCL Progression Risk
    CALQUENCE Plus Chemoimmunotherapy Reduced MCL Progression Risk

    16 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240616853829/en

    BUSINESSWIRE
    16 Jun 2024
    Share Share
    AstraZeneca aims for $80 bln in total revenue by 2030
    AstraZeneca aims for $80 bln in total revenue by 2030

    21 May 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-aims-deliver-80-billion-total-revenue-by-2030-2024-05-21/

    REUTERS
    21 May 2024
    Share Share
    Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma
    Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

    03 May 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html

    PRESS RELEASE
    03 May 2024
    Share Share